Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors
about
sameAs
Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors.Pathogenesis of human immunodeficiency virus infectionPhenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. Structural and biochemical analysesStructure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitorsNevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapyViral resistance to the thiazolo-iso-indolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptaseHuman immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutantsSusceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitorsNew tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogsThe PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptaseAnalysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptasePotent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptaseSpecific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitorsComprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitorsActivity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replicationResistance of human immunodeficiency virus type 1 to acyclic 6-phenylselenenyl- and 6-phenylthiopyrimidinesMutational sensitivity patterns define critical residues in the palm subdomain of the reverse transcriptase of human immunodeficiency virus type 1.Expression of reverse transcriptase from feline immunodeficiency virus in Escherichia coli.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT.Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcriptionThe phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.Human immunodeficiency virus type 2 reverse transcriptase activity in model systems that mimic steps in reverse transcription.Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not.Antiviral therapy for human immunodeficiency virus infectionsPharmacokinetics of nevirapine: initial single-rising-dose study in humans.Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy.Mutational analysis of the fingers domain of human immunodeficiency virus type 1 reverse transcriptase.The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.Nevirapine alters the cleavage specificity of ribonuclease H of human immunodeficiency virus 1 reverse transcriptase.The Y181C substitution in 3'-azido-3'-deoxythymidine-resistant human immunodeficiency virus, type 1, reverse transcriptase suppresses the ATP-mediated repair of the 3'-azido-3'-deoxythymidine 5'-monophosphate-terminated primer.New developments in the chemotherapy of lentivirus (human immunodeficiency virus) infections: sensitivity/resistance of HIV-1 to non-nucleoside HIV-1-specific inhibitors.Construction of the chimeric reverse transcriptase of simian immunodeficiency virus sensitive to nonnucleoside reverse transcriptase inhibitor.Antiviral activity of 4-benzyl pyridinone derivatives as HIV-1 reverse transcriptase inhibitors.The structure of FIV reverse transcriptase and its implications for non-nucleoside inhibitor resistance.
P2860
Q24540388-1C9EAB2F-4C21-496B-924C-10DCEF45E56BQ24634681-52EA2AE0-3052-4AA5-AF02-DFB2D5D7A1D5Q27621483-402A2A28-EDEB-4886-BF65-5E992BFC71A9Q27729365-A7C783B1-07FC-4D8F-9F4A-FFA26C9F9A30Q28316336-8714AA96-5F12-4746-9933-E38CB83D3BB8Q28342745-6847933D-33FD-49C2-A3F3-9AEB05DB209EQ28367526-643D03DC-3560-4D94-A40B-B4FFEC58DE8EQ28367531-9C78B543-B2A2-4672-A92E-8D5448682EC7Q28367570-EBFC3C3F-F23D-4D8F-9276-AEA554F8548AQ28367590-B4094442-AC4D-4DD0-81B0-5CD805F3E6B0Q28367654-48E45E92-EFCD-4457-A25E-ED583E31F68EQ28367759-B7D31199-8FAA-4087-AFC1-3B8045A56456Q28368003-D0C9597B-30F9-48D7-B375-57BE37B53153Q28368005-E5202258-59F3-46FE-8A99-19EE9B2A7431Q28368032-8A916C61-7CF4-4B16-9F00-7CAE97408649Q28368052-61DE3F44-19E3-4DB2-A20E-8D2DC2A3CEA5Q28368053-38F2EF4F-DBBB-4227-9A79-A6FD11A73F01Q28368381-D54E36D5-8F5A-4FDB-9327-BEA1E09CA44CQ30416860-F20FED12-0E45-4243-B96C-F02B1734F264Q33750039-DBF4FDA8-7C15-481D-A59C-46D7A64BAACFQ33906239-10414699-9B22-44D6-A93A-41D56E8037B7Q34181367-C2251787-C3CA-4A9D-9129-A14AA8F746A3Q35122784-01B78626-9142-46E9-BF45-0E8D96B5864DQ35123663-CFC9DC70-7280-4420-96F9-807E820EE781Q35149625-02420D80-9FE5-489A-92DD-01BD010E1676Q35312562-C0E36E4F-CC4D-4320-9E86-186BB0F03289Q35366050-2852A35F-3D99-45E1-B03C-A9A0404A14E7Q35808226-B4177B48-3639-431D-B4E7-DF662F81DCE2Q35842525-4C0D65CD-CBCE-4D6A-86EB-72B6A58CAC18Q36687547-004178BD-BD28-4147-859E-3E23D172EBB1Q37018369-A2B0F16B-654F-4748-BB4E-E313B22AB13FQ37682768-84DCFDC9-CB1E-4FA4-A32C-65C331AC199CQ38297932-FB37D62A-ED5E-43A2-92F7-074424E9C33DQ38351813-B4EF9729-1216-4084-86FD-66ACD7CDD4B9Q40390744-6378E3C1-6C66-4B59-B098-7DE3382BBDF4Q45756374-A8BE42D1-08B7-4D10-A331-5C079B3094EAQ46576605-4299B5C5-8BB4-4231-9B80-941B0CF1BA8BQ47549305-F7D25C11-D662-454A-A722-C071CB6FB0BF
P2860
Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors
description
1991 nî lūn-bûn
@nan
1991 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Chimeric human immunodeficienc ...... onnucleoside analog inhibitors
@ast
Chimeric human immunodeficienc ...... onnucleoside analog inhibitors
@en
Chimeric human immunodeficienc ...... onnucleoside analog inhibitors
@nl
type
label
Chimeric human immunodeficienc ...... onnucleoside analog inhibitors
@ast
Chimeric human immunodeficienc ...... onnucleoside analog inhibitors
@en
Chimeric human immunodeficienc ...... onnucleoside analog inhibitors
@nl
prefLabel
Chimeric human immunodeficienc ...... onnucleoside analog inhibitors
@ast
Chimeric human immunodeficienc ...... onnucleoside analog inhibitors
@en
Chimeric human immunodeficienc ...... onnucleoside analog inhibitors
@nl
P2093
P2860
P356
P1476
Chimeric human immunodeficienc ...... onnucleoside analog inhibitors
@en
P2093
P2860
P304
P356
10.1073/PNAS.88.21.9878
P407
P577
1991-11-01T00:00:00Z